Pharmaceutical companies could reduce the cost of drug development thanks to a new partnership that aims to scale the next generation of digital clinical trials.
mHealth
Global technology company HCL Technologies (HCL) has teamed up with Oracle Health Sciences to help life sciences companies implement technologies to improve clinical trials and reduce the cost of drug development.
The collaboration will utilise HCL’s Faster Intelligent Trials (FIT) Solution, alongside Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud).
HCL’s FIT solution is designed for a number of uses, including improving patient engagement, collecting patient reported outcomes, monitoring patient safety, improving medication adherence, or conducting e-visits during clinical trials to reduce patient and site burden.
The solution can also be applied for drugs already launched commercially, such as for remote patient monitoring, gathering real world evidence, or as an accompanying application for digital therapies.
The companies aim to help customers adopt mHealth technologies through a six-to-eight-week scheme. Companies that have more advanced mHealth initiatives can leverage the HCL FIT solution using Oracle mHealth Cloud “as a service” for a specific clinical trial.
Shrikanth Shetty, executive vice president and North America business head for life sciences and healthcare at HCL, said: “Although many of our customers have already established a strong case for leveraging mHealth technologies in clinical trials or digital therapies through proof of concept, we still see a chasm between the potential and actual adoption at scale. As a strategic partner to a large number of life sciences companies, HCL offers a comprehensive portfolio of services to navigate the journey from concept to adoption and continues to support them through the operational support services during or beyond clinical trials.”
“The life sciences industry has a great opportunity to radically change the way we understand and interact with patients during clinical trials. The collaboration between Oracle Health Sciences and HCL enables clinical teams to establish digitally enabled clinical trial processes and new digital trial methods such as remote patient monitoring. This is a very exciting time for the pharma industry as new technologies such as mHealth continue to accelerate clinical trials and speed time to market for patients who are waiting,” said Jim Streeter, global vice president, product strategy, for Oracle Health Sciences.